<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016050</url>
  </required_header>
  <id_info>
    <org_study_id>HPY-HPDT-DA-013-RWE-01</org_study_id>
    <nct_id>NCT05016050</nct_id>
  </id_info>
  <brief_title>Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)</brief_title>
  <official_title>A Real-World Evidence, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of HPDT-DA-013 Digital Therapeutic in the Treatment of Major Depressive Disorder(MDD)and Generalized Anxiety Disorder(GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Happify Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Happify Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will&#xD;
      use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety&#xD;
      measures during this time. After the treatment period, participants will be followed monthly&#xD;
      for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the safety and efficacy of HPDT-DA-013 digital therapeutic in&#xD;
      adults ages 22 years and older with MDD or GAD. Participants access HPDT-DA-013 on their&#xD;
      smart device or computer and complete treatment over a period of 8-10 weeks. During the&#xD;
      treatment period, participants complete PHQ-9 and GAD-7 assessments, as well as safety and&#xD;
      medication use questionnaires. After 8-10 weeks, participants will complete end-of-treatment&#xD;
      assessments, and access to HPDT-DA-013 will be removed. Participants are then followed for a&#xD;
      period of 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Health Questionnaire-9 (PHQ-9)</measure>
    <time_frame>baseline to end of treatment (8-10 weeks)</time_frame>
    <description>A 9-item self-report measure to assess symptoms of depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generalized Anxiety Disorder-7 (GAD-7)</measure>
    <time_frame>baseline to end of treatment (8-10 weeks)</time_frame>
    <description>A 7-item self-report measure to assess symptoms of anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PHQ-9</measure>
    <time_frame>Through study completion, average of 14 months</time_frame>
    <description>A 9-item self-report measure to assess symptoms of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7</measure>
    <time_frame>Through study completion, average of 14 months</time_frame>
    <description>A 7-item self-report measure to assess symptoms of anxiety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Digital therapeutic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HPDT-DA-013</intervention_name>
    <description>Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).</description>
    <arm_group_label>Digital therapeutic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 22 years or older at the time of screening&#xD;
&#xD;
          2. Meets DSM-5 diagnostic criteria for Major Depressive Disorder or Generalized Anxiety&#xD;
             Disorder&#xD;
&#xD;
          3. Access to and willingness to use computer equipment/smartphone compatible with the&#xD;
             product platform over a functional network for the study duration&#xD;
&#xD;
          4. Currently residing in the United States&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Risk of suicide or has attempted suicide within 24 months of the screening visit&#xD;
&#xD;
          2. Moderate to severe substance use disorder&#xD;
&#xD;
          3. Current co-morbid psychiatric diagnosis including PTSD, Schizophrenia, Bipolar&#xD;
             Disorder I or II, or Borderline Personality Disorder&#xD;
&#xD;
          4. Currently pregnant or planning to become pregnant during the treatment period&#xD;
&#xD;
        Note: Other protocol-defined inclusion/exclusion criteria applied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Vilardaga, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra McGriff</last_name>
    <phone>800-264-6428</phone>
    <email>sandra@happify.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Happify Health (Remote)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra McGriff</last_name>
      <email>sandra@happify.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

